GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » Capex-to-Operating-Cash-Flow

3SBio, (FRA:YFK) Capex-to-Operating-Cash-Flow : 0.70 (As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

3SBio,'s Capital Expenditure for the six months ended in Dec. 2016 was €-58.06 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2016 was €83.50 Mil.

Hence, 3SBio,'s Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2016 was 0.70.


3SBio, Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for 3SBio,'s Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, Capex-to-Operating-Cash-Flow Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.29 0.07 0.21 0.46

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.08 0.41 0.11 0.70

Competitive Comparison of 3SBio,'s Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, 3SBio,'s Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio,'s Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio,'s Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where 3SBio,'s Capex-to-Operating-Cash-Flow falls into.



3SBio, Capex-to-Operating-Cash-Flow Calculation

3SBio,'s Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2016 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-63.846) / 137.591
=0.46

3SBio,'s Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2016 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-58.058) / 83.499
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio,  (FRA:YFK) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


3SBio, Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of 3SBio,'s Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines